PART I Overview We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA ...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073472 | EDGAR | 97K words |
| 2025-03-04 | 2024-12-31 | 0000950170-25-031322 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0000950170-24-026876 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009319 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001564590-22-008414 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010718 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-007972 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005671 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005308 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004649 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-273288 | EDGAR | 23K words |
| 2025-07-30 | 2025-06-30 | 0000950170-25-099884 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066404 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124595 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093341 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0000950170-24-057457 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061544 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037601 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0000950170-23-016888 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024171 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016653 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009469 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-125092 | EDGAR | 2K words |
| 2026-02-26 | 0001193125-26-073437 | EDGAR | — |
| 2026-02-02 | 0001193125-26-032698 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009784 | EDGAR | — |
| 2025-12-11 | 0001193125-25-314746 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310595 | EDGAR | — |
| 2025-11-17 | 0001193125-25-283929 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273278 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256682 | EDGAR | — |
| 2025-09-24 | 0001193125-25-214176 | EDGAR | — |
242 total filings indexed. 210 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001631574 |
| Ticker | WVE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | U0 |
| Website | https://www.wavelifesciences.com |
| Listed | 2015-11-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report